Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical cord-derived mesenchymal stem cell transplantation for chronic obstructive pulmonary disease
ISRCTN70443938Phase 2Completed
- Sponsor
- Stem Cell Institute
- Start
- May 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic umbilical cord-derived mesenchymal stem cells in chronic obstructive pulmonary disease (COPD), sponsored by Stem Cell Institute. Primary endpoint: Safety and pulmonary function improvement. Started May 2018; status: completed.
02
Drugs
allogeneic umbilical cord-derived mesenchymal stem cells
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ISRCTN70443938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN70443938.